IL148621A0 - Oncolytic virus - Google Patents
Oncolytic virusInfo
- Publication number
- IL148621A0 IL148621A0 IL14862100A IL14862100A IL148621A0 IL 148621 A0 IL148621 A0 IL 148621A0 IL 14862100 A IL14862100 A IL 14862100A IL 14862100 A IL14862100 A IL 14862100A IL 148621 A0 IL148621 A0 IL 148621A0
- Authority
- IL
- Israel
- Prior art keywords
- virus
- tumor cell
- pkr
- oncolytic virus
- differential susceptibility
- Prior art date
Links
- 244000309459 oncolytic virus Species 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 4
- 210000004881 tumor cell Anatomy 0.000 abstract 3
- 241000711975 Vesicular stomatitis virus Species 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 241000709664 Picornaviridae Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 244000052637 human pathogen Species 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 230000035899 viability Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20251—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39787399A | 1999-09-17 | 1999-09-17 | |
PCT/US2000/025510 WO2001019380A2 (en) | 1999-09-17 | 2000-09-18 | Oncolytic virus |
Publications (1)
Publication Number | Publication Date |
---|---|
IL148621A0 true IL148621A0 (en) | 2002-09-12 |
Family
ID=23573018
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14862100A IL148621A0 (en) | 1999-09-17 | 2000-09-18 | Oncolytic virus |
IL148621A IL148621A (en) | 1999-09-17 | 2002-03-11 | Use of a virus for the manufacture of a medicament for reducing the viability of tumor cells and some isolated nucleic acid sequences |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL148621A IL148621A (en) | 1999-09-17 | 2002-03-11 | Use of a virus for the manufacture of a medicament for reducing the viability of tumor cells and some isolated nucleic acid sequences |
Country Status (13)
Country | Link |
---|---|
EP (2) | EP1218019B1 (es) |
JP (1) | JP5060694B2 (es) |
CN (1) | CN1289098C (es) |
AT (2) | ATE319460T1 (es) |
AU (1) | AU782402B2 (es) |
CA (1) | CA2386920C (es) |
DE (2) | DE60041210D1 (es) |
ES (2) | ES2320239T3 (es) |
HK (2) | HK1044708B (es) |
IL (2) | IL148621A0 (es) |
MX (1) | MXPA02002772A (es) |
NZ (4) | NZ517573A (es) |
WO (1) | WO2001019380A2 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
US7306902B2 (en) * | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
JP5208343B2 (ja) | 2000-06-26 | 2013-06-12 | ウェルスタット バイオロジクス コーポレイション | ウイルスを用いる細胞の浄化 |
US7122182B2 (en) | 2001-05-11 | 2006-10-17 | Wellstat Biologics Corporation | Oncolytic virus therapy |
EP1411880B1 (en) * | 2001-07-11 | 2018-04-25 | University of Miami | Recombinant vsv for the treatment of tumor cells |
AU2008201293B2 (en) * | 2001-07-11 | 2011-08-18 | University Of Miami | Recombinant VSV for the treatment of tumor cells |
JP2004099584A (ja) | 2002-05-02 | 2004-04-02 | Keio Gijuku | Hsvを用いた抗腫瘍剤 |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
ES2319424T3 (es) * | 2003-03-27 | 2009-05-07 | Ottawa Health Research Institute | Virus mutantes de la estomatitis vesivular y sus usos. |
US7731974B2 (en) * | 2003-03-27 | 2010-06-08 | Ottawa Hospital Research Institute | Mutant vesicular stomatitis viruses and uses thereof |
WO2005117557A2 (en) | 2004-06-01 | 2005-12-15 | San Diego State University Foundation | Expression system |
CN101065144B (zh) * | 2004-08-20 | 2012-06-13 | 溶瘤病毒有限公司 | 治疗血液癌症的方法和组合物 |
KR101295733B1 (ko) | 2004-08-20 | 2013-08-13 | 비랄리틱스 리미티드 | 혈액암의 치료방법 및 조성물 |
WO2007099401A2 (en) | 2005-08-01 | 2007-09-07 | University Technologies International, Inc. | Oncolytic attenuated reoviruses for treatment of proliferative disorders |
US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
ES2741138T3 (es) * | 2006-09-15 | 2020-02-10 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Rhabdovirus oncolítico de Farmington |
US10369171B2 (en) | 2007-03-13 | 2019-08-06 | Virocure, Inc. | Attenuated reoviruses for selection of cell populations |
PE20091104A1 (es) * | 2007-12-21 | 2009-07-18 | Wyeth Corp | Virus de la estomatitis vesicular atenuado modificado geneticamente, composiciones y metodos de uso del mismo |
WO2010020056A1 (en) * | 2008-08-21 | 2010-02-25 | Ottawa Hospital Research Institute | Engineered synergistic oncolytic viral symbiosis |
DE102008050860A1 (de) * | 2008-10-08 | 2010-04-15 | Dorothee Von Laer | LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren |
EP2408473B1 (en) | 2009-03-16 | 2016-03-16 | McMaster University | Vaccination methods |
US9045729B2 (en) * | 2009-12-10 | 2015-06-02 | Ottawa Hospital Research Institute | Oncolytic rhabdovirus |
US9428736B2 (en) | 2010-09-02 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
US9364532B2 (en) | 2011-06-08 | 2016-06-14 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Compositions and methods for glioblastoma treatment |
DK2763696T3 (en) | 2011-10-07 | 2018-10-15 | Isd Immunotech Aps | Identification of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses |
CN105658790A (zh) | 2013-02-21 | 2016-06-08 | 东安大略研究所儿童医院有限公司 | 疫苗组合物 |
DK2983706T3 (en) | 2013-04-10 | 2021-06-14 | Univ Aarhus | Use of Immune Suppressive Domains as Medicaments |
US10066214B2 (en) | 2013-06-14 | 2018-09-04 | Turnstone Limited Partnership | Compositions and methods for enhancing virus replication |
ES2566146T3 (es) * | 2013-07-16 | 2016-04-11 | Sia Latima | Virus de ARN oncolítico genéticamente estable, método de fabricación y uso del mismo |
WO2016013008A1 (en) * | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
CN105233285B (zh) * | 2015-09-06 | 2018-10-12 | 广州威溶特医药科技有限公司 | Epac直接或间接激动剂与溶瘤病毒的联合应用 |
US10610583B2 (en) | 2017-08-31 | 2020-04-07 | Regents Of The University Of Minnesota | Methods and compositions for treating glioma and medulloblastoma brain tumors using the zika virus |
EP3684786A1 (en) * | 2017-09-22 | 2020-07-29 | Centre National de la Recherche Scientifique (CNRS) | Mutated glycoprotein of vesicular stomatitis virus |
CN110499297B (zh) * | 2019-08-29 | 2021-07-09 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
CN116724110A (zh) * | 2020-08-14 | 2023-09-08 | 上海行深生物科技有限公司 | 重组溶瘤病毒及其构建方法和用途 |
WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1118403B (de) | 1960-01-27 | 1961-11-30 | Hoechst Ag | Verfahren zur Gewinnung von antitumorwirksamen Sporen |
GB1069144A (en) | 1963-07-10 | 1967-05-17 | Merck & Co Inc | Method for the treatment of malignant tumors |
US4806347A (en) | 1985-12-11 | 1989-02-21 | Schering Corporation | Interferon combinations |
AU673827B2 (en) * | 1992-03-24 | 1996-11-28 | United Cancer Research Institute | Vaccine containing live virus for therapy of viral diseases and malignancies |
GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
US7153510B1 (en) * | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
EP1314430A1 (en) | 1996-01-25 | 2003-05-28 | The University Court Of The University Of Glasgow | Treatment of non-neuronal cancer using HSV mutant |
JP4434478B2 (ja) * | 1997-07-11 | 2010-03-17 | イエール ユニバーシティー | リエンジニアリングされた外被を有するラブドウイルス |
AU9603898A (en) * | 1997-10-09 | 1999-05-03 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
CA2316033A1 (en) * | 1997-12-22 | 1999-07-01 | The University Of Tennessee Research Corporation | Recombinant rhabdovirus containing a heterologous fusion protein |
EP1061806A4 (en) * | 1998-03-12 | 2001-09-12 | Univ Pennsylvania | PRODUCTIVE CELLS FOR REPLICATION-SELECTIVE VIRUSES FOR TREATING Vicious DISEASES |
AU771110B2 (en) * | 1998-06-12 | 2004-03-11 | Mount Sinai School Of Medicine Of The City University Of New York, The | Novel methods and interferon deficient substrates for the propagation of viruses |
CN1477964A (zh) * | 1999-04-15 | 2004-02-25 | 应用病毒治疗肿瘤 |
-
2000
- 2000-09-18 CN CNB008158983A patent/CN1289098C/zh not_active Expired - Fee Related
- 2000-09-18 NZ NZ517573A patent/NZ517573A/en not_active IP Right Cessation
- 2000-09-18 ES ES05025974T patent/ES2320239T3/es not_active Expired - Lifetime
- 2000-09-18 EP EP00965106A patent/EP1218019B1/en not_active Expired - Lifetime
- 2000-09-18 CA CA2386920A patent/CA2386920C/en not_active Expired - Fee Related
- 2000-09-18 NZ NZ523805A patent/NZ523805A/en not_active IP Right Cessation
- 2000-09-18 ES ES00965106T patent/ES2260057T3/es not_active Expired - Lifetime
- 2000-09-18 EP EP05025974A patent/EP1716858B9/en not_active Expired - Lifetime
- 2000-09-18 AT AT00965106T patent/ATE319460T1/de active
- 2000-09-18 MX MXPA02002772A patent/MXPA02002772A/es active IP Right Grant
- 2000-09-18 NZ NZ534307A patent/NZ534307A/en not_active IP Right Cessation
- 2000-09-18 DE DE60041210T patent/DE60041210D1/de not_active Expired - Lifetime
- 2000-09-18 JP JP2001523012A patent/JP5060694B2/ja not_active Expired - Fee Related
- 2000-09-18 NZ NZ534306A patent/NZ534306A/en not_active IP Right Cessation
- 2000-09-18 DE DE60026554T patent/DE60026554T2/de not_active Expired - Lifetime
- 2000-09-18 IL IL14862100A patent/IL148621A0/xx unknown
- 2000-09-18 AU AU75882/00A patent/AU782402B2/en not_active Ceased
- 2000-09-18 AT AT05025974T patent/ATE418341T1/de active
- 2000-09-18 WO PCT/US2000/025510 patent/WO2001019380A2/en active IP Right Grant
-
2002
- 2002-03-11 IL IL148621A patent/IL148621A/en not_active IP Right Cessation
- 2002-07-30 HK HK02105578.7A patent/HK1044708B/zh not_active IP Right Cessation
-
2006
- 2006-12-07 HK HK06113483.1A patent/HK1092713A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2386920A1 (en) | 2001-03-22 |
CA2386920C (en) | 2012-01-24 |
EP1716858A3 (en) | 2007-08-15 |
EP1716858A2 (en) | 2006-11-02 |
EP1716858B9 (en) | 2009-08-12 |
NZ534307A (en) | 2005-07-29 |
WO2001019380A2 (en) | 2001-03-22 |
ATE319460T1 (de) | 2006-03-15 |
AU782402B2 (en) | 2005-07-28 |
NZ517573A (en) | 2004-02-27 |
JP5060694B2 (ja) | 2012-10-31 |
IL148621A (en) | 2010-02-17 |
MXPA02002772A (es) | 2004-04-02 |
CN1496268A (zh) | 2004-05-12 |
EP1716858B1 (en) | 2008-12-24 |
ATE418341T1 (de) | 2009-01-15 |
DE60026554D1 (de) | 2006-05-04 |
JP2004525855A (ja) | 2004-08-26 |
HK1044708B (zh) | 2006-10-27 |
CN1289098C (zh) | 2006-12-13 |
HK1044708A1 (en) | 2002-11-01 |
EP1218019B1 (en) | 2006-03-08 |
HK1092713A1 (en) | 2007-02-16 |
DE60026554T2 (de) | 2006-09-28 |
WO2001019380A3 (en) | 2001-11-22 |
ES2320239T3 (es) | 2009-05-20 |
NZ523805A (en) | 2004-09-24 |
DE60041210D1 (de) | 2009-02-05 |
AU7588200A (en) | 2001-04-17 |
NZ534306A (en) | 2005-12-23 |
EP1218019A2 (en) | 2002-07-03 |
ES2260057T3 (es) | 2006-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1092713A1 (en) | Oncolytic virus | |
IL157504A0 (en) | Oncolytic virus therapy | |
MY133891A (en) | Polyethylene glycol modified interferon therapy | |
MY141594A (en) | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES | |
HK1127370A1 (en) | Mutant vesicular stomatitis viruses and use thereof | |
DE69333321D1 (de) | Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten. | |
DE69528751T2 (de) | Verwendung von Interferon-alpha 8 subtype zur Herstellung von Medikamenten zur Behandlung von Viralinfektionen der Leber | |
NZ516349A (en) | Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease | |
EP1217891A4 (en) | THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE | |
DK0721332T3 (da) | Fremgangsmåde II | |
ATE265204T1 (de) | Micropartikeln zur verwendung in nadellosen injektion | |
FI940375A0 (fi) | Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa | |
DE60136381D1 (de) | Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität | |
ATE89569T1 (de) | Haemoglobin mit reduziertem virusrisiko und dessen herstellung. | |
SG165996A1 (en) | Combination therapies with l-fmau for the treatment of hepatitis b virus infection | |
WO2003015714A3 (en) | Compositions and therapeutic methods for viral infection | |
WARFEL et al. | Production and initial characterization of guinea pig interferon | |
EP1143981A4 (en) | TREATMENT AND PREVENTION OF HIV AND OTHER VIRUS INFECTIONS | |
Czarniecki et al. | Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells | |
Eylan et al. | Resistance of aged cells to virus replication | |
DE69422980D1 (de) | Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen | |
AU6301398A (en) | Arrestable therapeutic viral agent | |
SU1565027A1 (ru) | Инактиватор вируса западного нила | |
UA23352A (uk) | beta- D- ГЛЮКОЗАМОHІЙHА СІЛЬ alРha-БРОМІЗОВАЛЕРІАHОВОЇ КИСЛОТИ, ЯКА МАЄ ПРОТИВІРУСHУ АКТИВHІСТЬ ВІДHОСHО ВІРУСУ ВЕЗИКУЛЯРHОГО СТОМАТИТУ, ВІРУСУ ПРОСТОГО ГЕРПЕСУ ТА КОРОHАВІРУСУ | |
Licking | Scrubbing the blood supply |